Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 16, Issue 1, 1996, Pages 21-33

  Borges, M ^a   Sculier, J P ^a   Paesmans, M ^a   Richez, M ^a   Bureau, G ^a   Dabouis, G ^a   Lecomte, J ^a   Michel, J ^a   Van Cutsem, O ^a   Schmerber, J ^a   Giner, V ^a   Berchier, M C ^a   Sergysels, R ^a   Mommen, P ^a   Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

non small cell lung cancer; prognostic factors; response to chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MITOMYCIN; VINDESINE;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

EID: 0031040699     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(96)00609-5     Document Type: Article

References (40)

1. [1] Bick RL. Coagulation abnormalities in malignancy: a review. Semin Tromb Hemost 1992; 18: 353.
2. [2] Brechot JM, Conard J, Samama M. Coagulation et cancers bronchopulmonaires. De la clinique à la biologie. Rev Mal Resp 1992; 9: 375-384.
3. [3] Bunn PA, Van Zandwigk N, Pastorino U et al. European School of Oncology First Euro-American Forum on Lung Cancer Treatment. Eur J Cancer 1994; 30A: 710-713.
4. [4] DeCaro L, Benfield JR. Lung cancer in young persons. J Thorac Cardiovasc Surg 1982; 83: 372-376.
5. [5] Donnadieu N, Paesmans M, Sculier JP. Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 1991; 7: 243-252.
6. [6] Fleiss JL. Statistical methods for rates and proportions. New York, John Wiley and Sons, 1981.
7. [7] Ganz PA, Vernon SE, Preston D, Coulson WF. Lung cancer in younger patients. West J Med 1980; 133: 373-378.
8. [8] Graziano SL, Mazid R, Newman N et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol 1989; 7: 1398-1406.
9. [9] Green MR, Ginsberg R, Ardizzoni A, et al. Induction Therapy for Stage III NSCLC: a Consensus Report. Lung Cancer 1994; 11(suppl.): S9-S10.
10. [10] Grilli R, Andrew D, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
11. [11] Herbert SH, Curram Jr WJ, Rosenthal SA, Stafford PM, et al. Adverse influence of younger age on outcome in patients with non-small cell lung carcinoma (NSCLC) treated with radiation therapy (RT) alone. Int J Radiat Oncol Biol Phys 1992; 24: 37-42.
12. [12] Honio Y, Takahashi T, Kuroishi T et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1-4.
13. [13] Hosmer DW, Lemeshow S. Applied logistic regression. New York, John Wiley and Sons, 1989.
14. [14] Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-1441.
15. [15] Isobe H, Miyamoto H, Shimizu T et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990; 65: 1391-1395.
16. [16] Jubeliner SJ, Wilson RA. Lung cancer in patients younger than 40 years of age. Cancer 1991; 67: 1436-1438.
17. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-5191.
18. [18] Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7: 1087-1092.
19. [19] Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556-1562.
20. [20] Klastersky J, Sculier JP, Ravez P et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1986; 4: 1780-1786.
21. [21] Klastersky J, Sculier JP, Ries et al. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluororacile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 1994; 11: 373-384.
22. [22] Klastersky J, Sculier JP, Weerts D et al. Combination chemotherapy with cisplatin, etoposide and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 1983; 67: 727-730.
23. [23] Marino P, Preatoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer. Cancer 1995; 76: 593-601.
24. [24] Mitsudomi T, Oyama T, Kusano T et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 2018-2023.
25. [25] Mitsudomi T, Steinberg SM, Ole HK et al. K-ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4999-5002.
26. [26] Nie NH, Hull CTT, Jenkins JG et al: Statistical package for the social sciences. SPSS Inc, Chicago, 1988.
27. [27] Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data of individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
28. [28] O'Connell JP, Kris MG, Gralla RJ et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4: 1604-1614.
29. [29] Paesmans M, Sculier JP, Libert P, Bureau G et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1052 patients: J Clin Oncol 1995; 13: 1221-1230.
30. [30] Pezzella F, Turley H, Kuzu I et al. bcl-2 Protein in non-small cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
31. [31] Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153-158.
32. [32] Sahin AA, RO JY, El-Naggar et al. Flow cytometric analysis of the DNA content in non-small cell lung cancer, ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer 1990; 65: 530-537.
33. [33] Sculier JP, Klastersky J, Giner V et al. Phase II randomized trial comparing high-dose cisplatin with moderate dose cisplatin and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 994; 12: 353-359.
34. [34] Sculier JP, Paesmans M, Libert P, Bureau G et al. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced non-small cell lung cancer. Eur J Cancer 1994; 30A: 1342-1347.
35. [35] Slebos RJC, Kibbelaar RE, Dalesio O et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990:323:561-563.
36. [36] Sorensen JB, Badsberg JH, Hansen HH. Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications. Br J Cancer 1989; 60: 389-393.
37. [37] Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
38. [38] Van Houtte P, Klastersky J, Renaud A et al. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for non-small cell lung cancer. In Arriagada R: Treatment Modalities in Lung Cancer. Antibiot Chemother Basel, Karger 1988; 41: 131-137.
39. [39] Volm M, Drings P, Wodrick W. Prognostic significance of the expression of c-fos, c-jun and c-erb B-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 1993; 119: 507-510.
40. [40] Volm M, Drings P, Wodrick W. Prognostic value of oncoproteins for the survival of patients with non-small cell lung carcinoma. Int J Oncol 1993; 2: 767-772.